Efficacy and safety of abacavir plus efavirenz as a salvage regimen in HIV-infected individuals after 48 weeks
AIDS, ISSN: 0269-9370, Vol: 16, Issue: 7, Page: 1077-1078
2002
- 9Citations
- 2Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
The efficacy and safety of abacavir and efavirenz plus background therapy were evaluated in 50 heavily antiretroviral pre-treated patients. In this retrospective analysis, the overall antiretroviral efficacy of abacavir and efavirenz plus background therapy was limited in the salvage situation, but immunological benefit was still achieved for most patients. The tolerability of the salvage regimen seems to be good, although the drop-out rate during the first 4 weeks of treatment was high.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0037013094&origin=inward; http://dx.doi.org/10.1097/00002030-200205030-00018; http://www.ncbi.nlm.nih.gov/pubmed/11953478; http://journals.lww.com/00002030-200205030-00018; https://dx.doi.org/10.1097/00002030-200205030-00018; https://journals.lww.com/aidsonline/Fulltext/2002/05030/Efficacy_and_safety_of_abacavir_plus_efavirenz_as.18.aspx
Ovid Technologies (Wolters Kluwer Health)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know